Valuation: Kamada Ltd.

Market Cap 128.29Cr 42Cr 36Cr 34Cr 31Cr 59Cr 3.99TCr 60Cr 399.09Cr 156.63Cr 1.99TCr 157.15Cr 153.7Cr 6.67TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 128.29Cr 42Cr 36Cr 34Cr 31Cr 59Cr 3.99TCr 60Cr 399.09Cr 156.63Cr 1.99TCr 157.15Cr 153.7Cr 6.67TCr EV / Sales 2026 *
2.14x
EV / Sales 2027 * 1.96x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/07/2015
Director of Finance/CFO 55 31/12/2017
Chief Operating Officer 53 01/11/2016
Director TitleAgeSince
Director/Board Member 75 13/12/1990
Chairman 77 07/03/2013
Chairman 55 12/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.28% - - 42Cr
+3.29%+16.25%+39.81%+2.79% 7.62TCr
-2.75%+48.50%+48.50%+48.50% 4.78TCr
+2.72%-9.39%+17.04%+176.83% 4.89TCr
-3.81%+7.74%-54.57%-54.17% 4.14TCr
-2.40%+0.38%+58.55%-24.89% 3TCr
-2.82%+1.57%+59.59%+87.57% 2.42TCr
-5.35%+1.39%+85.45%-53.41% 2.18TCr
-1.59%-3.61%-11.53%+150.58% 1.92TCr
-0.42%+2.89%+74.55%+128.45% 1.71TCr
Average -1.74%+1.48%+35.27%+51.36% 3.63TCr
Weighted average by Cap. -1.49%+2.98%+30.74%+43.63%

Financials

2026 *2027 *
Net sales 60Cr 20Cr 17Cr 16Cr 15Cr 27Cr 1.87TCr 28Cr 186.73Cr 73Cr 930.43Cr 74Cr 72Cr 3.12TCr 65Cr 21Cr 19Cr 17Cr 16Cr 30Cr 2.04TCr 30Cr 203.61Cr 80Cr 1.01TCr 80Cr 78Cr 3.4TCr
Net income 7.39Cr 2.41Cr 2.1Cr 1.95Cr 1.79Cr 3.38Cr 230.06Cr 3.43Cr 23Cr 9.02Cr 114.53Cr 9.05Cr 8.85Cr 384.05Cr 11Cr 3.44Cr 2.99Cr 2.78Cr 2.55Cr 4.82Cr 328.25Cr 4.9Cr 33Cr 13Cr 163.42Cr 13Cr 13Cr 547.96Cr
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-